188 related articles for article (PubMed ID: 25701036)
41. Biomineralized Gd
Hao T; Chen Q; Qi Y; Sun P; Chen D; Jiang W; Liu K; Sun H; Li L; Ding J; Li Z
Adv Healthc Mater; 2019 Dec; 8(24):e1901005. PubMed ID: 31738019
[TBL] [Abstract][Full Text] [Related]
42. From one to all: self-assembled theranostic nanoparticles for tumor-targeted imaging and programmed photoactive therapy.
Li X; Wang X; Zhao C; Shao L; Lu J; Tong Y; Chen L; Cui X; Sun H; Liu J; Li M; Deng X; Wu Y
J Nanobiotechnology; 2019 Feb; 17(1):23. PubMed ID: 30711005
[TBL] [Abstract][Full Text] [Related]
43. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
44. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
45. Biodegradation model of porous silicon nanoparticles.
Gongalsky MB; Sviridov AP; Bezsudnova YI; Osminkina LA
Colloids Surf B Biointerfaces; 2020 Jun; 190():110946. PubMed ID: 32172165
[TBL] [Abstract][Full Text] [Related]
46. Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T
Gao L; Yu J; Liu Y; Zhou J; Sun L; Wang J; Zhu J; Peng H; Lu W; Yu L; Yan Z; Wang Y
Theranostics; 2018; 8(1):92-108. PubMed ID: 29290795
[TBL] [Abstract][Full Text] [Related]
47. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
Wang Q; Sui G; Wu X; Teng D; Zhu L; Guan S; Ran H; Wang Z; Wang H
Acta Biomater; 2020 Jan; 102():367-383. PubMed ID: 31778831
[TBL] [Abstract][Full Text] [Related]
48. Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy.
Kinnari PJ; Hyvönen ML; Mäkilä EM; Kaasalainen MH; Rivinoja A; Salonen JJ; Hirvonen JT; Laakkonen PM; Santos HA
Biomaterials; 2013 Dec; 34(36):9134-41. PubMed ID: 24008034
[TBL] [Abstract][Full Text] [Related]
49. Indocyanine green-incorporating nanoparticles for cancer theranostics.
Wang H; Li X; Tse BW; Yang H; Thorling CA; Liu Y; Touraud M; Chouane JB; Liu X; Roberts MS; Liang X
Theranostics; 2018; 8(5):1227-1242. PubMed ID: 29507616
[TBL] [Abstract][Full Text] [Related]
50. Self-Monitoring and Self-Delivery of Photosensitizer-Doped Nanoparticles for Highly Effective Combination Cancer Therapy in Vitro and in Vivo.
Zhang J; Liang YC; Lin X; Zhu X; Yan L; Li S; Yang X; Zhu G; Rogach AL; Yu PK; Shi P; Tu LC; Chang CC; Zhang X; Chen X; Zhang W; Lee CS
ACS Nano; 2015 Oct; 9(10):9741-56. PubMed ID: 26390118
[TBL] [Abstract][Full Text] [Related]
51. Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with
Hervella P; Dam JH; Thisgaard H; Baun C; Olsen BB; Høilund-Carlsen PF; Needham D
J Control Release; 2018 Dec; 291():11-25. PubMed ID: 30291986
[TBL] [Abstract][Full Text] [Related]
52. Merging metal organic framework with hollow organosilica nanoparticles as a versatile nanoplatform for cancer theranostics.
Chen L; Zhang J; Zhou X; Yang S; Zhang Q; Wang W; You Z; Peng C; He C
Acta Biomater; 2019 Mar; 86():406-415. PubMed ID: 30625415
[TBL] [Abstract][Full Text] [Related]
53. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
[TBL] [Abstract][Full Text] [Related]
54. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics.
Huang Y; Mao K; Zhang B; Zhao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):763-771. PubMed ID: 27770953
[TBL] [Abstract][Full Text] [Related]
55. An Assessment of In-vitro and In-vivo Evaluation Methods for Theranostic Nanomaterials.
Parashar P; Singh N; Alka ; Maurya P; Saraf SA
Curr Pharm Des; 2022; 28(2):78-90. PubMed ID: 34348616
[TBL] [Abstract][Full Text] [Related]
56. Multifunctional gold-based nanocomposites for theranostics.
Dykman LA; Khlebtsov NG
Biomaterials; 2016 Nov; 108():13-34. PubMed ID: 27614818
[TBL] [Abstract][Full Text] [Related]
57. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
[TBL] [Abstract][Full Text] [Related]
58. Composite Porous Silicon-Silver Nanoparticles as Theranostic Antibacterial Agents.
Kim T; Braun GB; She ZG; Hussain S; Ruoslahti E; Sailor MJ
ACS Appl Mater Interfaces; 2016 Nov; 8(44):30449-30457. PubMed ID: 27754645
[TBL] [Abstract][Full Text] [Related]
59. Tumor-Specific Endogenous Fe
Fan Z; Jiang B; Zhu Q; Xiang S; Tu L; Yang Y; Zhao Q; Huang D; Han J; Su G; Ge D; Hou Z
ACS Appl Mater Interfaces; 2020 Apr; 12(13):14884-14904. PubMed ID: 32167740
[TBL] [Abstract][Full Text] [Related]
60. Comparative study on radiolabeling and biodistribution of core-shell silver/polymeric nanoparticles-based theranostics for tumor targeting.
Farrag NS; El-Sabagh HA; Al-Mahallawi AM; Amin AM; AbdEl-Bary A; Mamdouh W
Int J Pharm; 2017 Aug; 529(1-2):123-133. PubMed ID: 28624660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
